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Clinical Note 
Potency of Current Levothyroxine Preparations Evaluated by 
High-Performance Liquid Chromatography 
Sheldon S. Stoffer, MD,* and Walter E. Szpunar, PhD* 
Ten different levothyroxine products manufactured by six companies were analyzed by high-
performance liquid chromatography. Although nine products met the United States Pharmacopeia 
requirements, one product was found to have only 47% of expected potency. Until these products 
become more uniform, we would not recommend interchangeability of levothyroxine preparations. 
(Henry Ford Hosp MedJ 1988;36:64-5) 
In 1980 we demonsttated that the mean thyroxine content can be different in generic tablets when compared to that of brand name 
products. In addition, we demonstrated that a brand name prod-
uct (Synthroid®) had only 78% of expected potency (1). Since 
then, the United States Pharmacopeia (USP) requirements have 
been modified so that manufacturers must evaluate levothyrox-
ine content by high-performance liquid chromatography 
(HPLC) (2). In 1984 we reported that Synthroid® had been refor-
mulated and had 100% of expected potency (3). We reassessed 
the content of a number of manufacturers' products using HPLC 
to determine if these products are currently more uniform. 
Materials and Methods 
Ten different levothyroxine products manufactured by six 
companies were analyzed by HPLC (Applied Analytical Labo-
ratories, Wilmington, NC) (2). Local drugstores were contacted 
until ten different levothyroxine products were obtained. 
Between 17 and 21 tablets of each product were analyzed. 
The tablets were split into two groups, and each group was 
batch-analyzed separately. The analysis for each product was 
completed in one day, and all products were analyzed over a 
three-day period. Analysis of each extraction was duplicated. 
Since two batch extractions were done on each product, each 
group of tablets was assayed four times. The only exception was 
product 10, which was submitted twice and treated as two sepa-
rate products. Therefore, product 10 was analyzed eight times. 
All tablets were 0.1 mg strength and were purchased in the fall of 
1986. The assays were performed in June 1987. 
Results 
The results of our analyses are shown in the Table. Nine prod-
ucts fell within the USP requirement of ± 10%, but product 10 
had only 47% of expected potency. 
Table 
Thyroxine Content of 100 pg Tablets* 
Expiration 
% of Expected Date 
Product Manufacturer Contentt (month/year) 
1 A 95 2/88 
2 B >)4 1/88 
3 C 95 3/88 
4 c 96 5/88 5 c 102 12/87 6 D 91 10/88 
7 c 9S 4/88 
8 ll 96 1/89 
9 F 100 10/87 
10 C 47 f48t 
145 
7/87 
*These levothyroxine products were distributed under ten different labels. 
tCoefficient of variation < 1.8%. 
tTwo separate submissions: coefficient of variation - 3.6% for combined analysis. 
Discussion 
A recent study by Dong et al (4) showed frequent non-
equivalence of levothyroxine products by tablet HPLC analysis. 
However, these levothyroxine products were purchased in 1981, 
before the introduction of the HPLC requirement for manufac-
turers. We suspect that the new USP HPLC requirement has im-
proved the uniformity of levothyroxine products. However, Fish 
et al (5) recently reported that one generic product had only 34% 
of expected potency. Our data show that yet another company 
had at least one lot (product 10) with less than expected potency 
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(47%). We admit that our study is limited. To better estimate the 
magnitude of the problem, a larger study evaluating different 
lots, different time periods, and different tablet strengths is 
needed. We hope this paper will stimulate investigators at re-
search centers where such a study may be feasible. 
The Food and Dmg Administration currently does not recom-
mend interchangeability of levothyroxine products (6). Nev-
ertheless, generic levothyroxine products are available and are 
being interchanged for each other and for the brand name prod-
ucts, at least in Michigan. The FDA's advice is not binding on 
the United States, and each state may allow interchangeability 
for the products that the FDA considers not interchangeable (6). 
We are concemed that levothyroxine products still show signifi-
cant variability by HPUC (in vitro) testing. The USP has no re-
quirement for bioavailability (in vivo) studies for levothyroxine 
products (7). Until levothyroxine products become more uni-
form, we agree with the FDA's position that these products not 
be interchanged. We hope that levothyroxine products will con-
tinue to be improved in the future. 
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